


## **PSJ2 Exh 152**

HIGHLY CONFIDENTIAL-SUBJECT TO PROTECTIVE ORDER

Confidential / Exempt from FOIA. Subject to FRE 408.




Donald Walker  
Senior Vice President  
Distribution Operations


MCK\_WVA\_000010

MCKMDL00403340

Confidential - Subject to Protective Order



MCK-WVAG-003-0001332



## Discussion Topics


---

- ▶ Public Health Issue
- ▶ DEA Focus
- ▶ McKesson Involvement
- ▶ Current Status
- ▶ Lifestyle Drug Monitoring Program



Confidential / Exempt from FOIA. Subject to FRE 408.


MCK\_WVA\_000011



## Public Health Issues

---

- ▶ Abuse of prescription drugs has risen 66% since 2000
- ▶ Hot capital hill topic
- ▶ Opioid painkillers kill more than cocaine and heroin combined
- ▶ Rogue Internet pharmacies distributing
  - Oxycodone C-II opioid analgesic painkiller
  - Hydrocodone C-II and C-III opioid painkiller
  - Phentermine C-IV appetite suppressant
  - Alprazolam C-IV antidepressant



Confidential / Exempt from FOIA. Subject to FRE 408.

MCK\_WVA\_000012

Confidential - Subject to Protective Order

MCK-WVAG-003-0001334

HIGHLY CONFIDENTIAL-SUBJECT TO PROTECTIVE ORDER

MCKMDL00403342





## DEA Focus


---

- ▶ Internet Pharmacies
  - Investigative work hours have doubled
  - Cutting supply critical to success
  - 218 investigations in 2006
- ▶ Wholesalers
  - DEA expects
    - We "know our customers"
    - Wholesalers accountable for controlling quantities shipped
    - 5000 dose units is "average"



Confidential / Exempt from FOIA. Subject to FRE 408.


MCK\_WVA\_000013



## McKesson Involvement

---

- ▶ Sept 05- DEA meeting in Wash DC
  - Outlined Internet issue
- ▶ Nov 05 – DEA notified McKesson
  - 6 pharmacies in Florida excessive Hydrocodone
- ▶ Jan 06 – Meeting with DEA in Wash DC
  - Clear message from DEA
- ▶ Oct 06 – Order to Show Cause
  - Response: Create MOU



Confidential / Exempt from FOIA. Subject to FRE 408.


MCK\_WVA\_000014

Confidential - Subject to Protective Order

MCK-WVAG-003-0001336

HIGHLY CONFIDENTIAL-SUBJECT TO PROTECTIVE ORDER

MCKMDL00403344



## Current Status

---

- ▶ Apr 07 – Meeting with DEA attorneys
  - Identified new customers and DC's
- ▶ What we have done
  - Created new report and process
  - Lifestyle Drug Monitoring Program
  - Drafted response to DEA
  - Added analyst to Regulatory group



Confidential / Exempt from FOIA. Subject to FRE 408.

MCK\_WVA\_000015

## Lifestyle Drug Monitoring Program (LDMP)

**McKESSON**  
*Empowering Healthcare*

---

STARTS MAY 1st

- ▶ Focus on four drugs
- ▶ Measure by "dose units" rather than sell units
- ▶ Establish threshold for excessive quantities – 8000 dose units
- ▶ Thorough due diligence of customers exceeding threshold
- ▶ Reducing orders to customers
- ▶ Documentation and reporting to DEA



7


NATIONAL OPERATIONS CONFERENCE 2007


MCK\_WVA\_000016



# Lifestyle Drug Monitoring Program (LDMP)

**McKESSON**  
Empowering Healthcare






## Daily Dosage Summary Report

---

- ▶ Captures data on the 4 Lifestyle drugs
  - Oxycodone, Hydrocodone, Phentermine, Alprazolam
- ▶ Generic base code
- ▶ 8000 dose unit threshold
- ▶ Report will be emailed daily to DCM and designees



Confidential / Exempt from FOIA. Subject to FRE 408.

MCK\_WVA\_000018

Confidential - Subject to Protective Order

MCK-WVAG-003-0001340

HIGHLY CONFIDENTIAL-SUBJECT TO PROTECTIVE ORDER

MCKMDL00403348